Compare FRHC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRHC | BIO |
|---|---|---|
| Founded | N/A | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 6.9B |
| IPO Year | 1996 | N/A |
| Metric | FRHC | BIO |
|---|---|---|
| Price | $138.20 | $285.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $339.75 |
| AVG Volume (30 Days) | 150.6K | ★ 431.5K |
| Earning Date | 06-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.29 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $2,191,291,000.00 | N/A |
| Revenue This Year | N/A | $2.74 |
| Revenue Next Year | N/A | $3.20 |
| P/E Ratio | $55.84 | ★ $9.72 |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $107.98 | $222.80 |
| 52 Week High | $194.01 | $343.12 |
| Indicator | FRHC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 47.20 |
| Support Level | $133.76 | $256.85 |
| Resistance Level | $138.47 | $288.48 |
| Average True Range (ATR) | 8.70 | 9.54 |
| MACD | -1.23 | -2.00 |
| Stochastic Oscillator | 12.52 | 1.12 |
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.